BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

CHMP rejects Sarepta’s Elevidys, changes mind on Lilly’s Kisunla
After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be approving the Duchenne muscular dystrophy gene...

More in BioWorld

BioWorld MedTech

EU approves €403M package for med tech
The European Commission approved up to €403 million ($472 million) in funding to support development of innovations in medical devices in the region. The funds will go...

More in BioWorld MedTech

BioWorld Science

Two cancer drugs combined modify Alzheimer’s disease in mice
Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...

More in BioWorld Science

BioWorld Asia

Livzon’s IL-17A/F meets phase III endpoints in plaque psoriasis
Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted at Fudan...

More in BioWorld Asia

BioWorld Insider Podcast

Robert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.